Marinus Pharmaceuticals (MRNS) News Today → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free MRNS Stock Alerts $1.33 -0.05 (-3.62%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineFY2027 EPS Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Lifted by Leerink Partnrsamericanbankingnews.com - May 12 at 3:50 AMEarnings Release: Here's Why Analysts Cut Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Price Target To US$8.00finance.yahoo.com - May 11 at 9:39 AMBuy Rating Affirmed for Marinus Pharmaceuticals Amidst Operational Progress and Strategic Cost Managementmarkets.businessinsider.com - May 10 at 6:33 PMOppenheimer Reaffirms Their Hold Rating on Marinus (MRNS)markets.businessinsider.com - May 10 at 2:15 AMHC Wainwright Weighs in on Marinus Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:MRNS)americanbankingnews.com - May 9 at 6:16 AMMarinus Pharmaceuticals (NASDAQ:MRNS) PT Lowered to $11.00americanbankingnews.com - May 9 at 5:04 AMMarinus Pharmaceuticals: Q1 Earnings Snapshotwashingtonpost.com - May 8 at 8:06 PMBuy Rating Affirmed for Marinus Pharmaceuticals Amid Positive Sales and Promising Drug Trialsmarkets.businessinsider.com - May 8 at 8:06 PMMarinus Pharmaceuticals GAAP EPS of -$0.68 misses by $0.02, revenue of $7.68M misses by $1.48Mmsn.com - May 8 at 8:06 PMMarinus Pharmaceuticals CEO to Speak at RBC Healthcare Conferencemsn.com - May 8 at 8:06 PMMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Resultsfinance.yahoo.com - May 8 at 7:10 AMMarinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Resultsbusinesswire.com - May 8 at 7:00 AMMarinus Pharmaceuticals (NASDAQ:MRNS) Price Target Lowered to $11.00 at HC Wainwrightmarketbeat.com - May 7 at 11:49 AMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Consensus Recommendation of "Moderate Buy" from Brokeragesamericanbankingnews.com - May 3 at 2:58 AMMarinus Pharmaceuticals (MRNS) Set to Announce Quarterly Earnings on Wednesdaymarketbeat.com - May 2 at 10:17 AMMarinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conferencebusinesswire.com - May 2 at 8:00 AMMarinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024finance.yahoo.com - May 1 at 11:06 AMabrdn plc Acquires New Holdings in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)marketbeat.com - April 28 at 5:29 AMMarinus Pharmaceuticals Inc (MRNS)investing.com - April 24 at 5:27 PMTruist Financial Trims Marinus Pharmaceuticals (NASDAQ:MRNS) Target Price to $10.00marketbeat.com - April 18 at 8:28 AMCantor Fitzgerald Comments on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)marketbeat.com - April 18 at 6:16 AMBaird Downgrades Marinus Pharmaceuticals (MRNS)msn.com - April 17 at 8:14 PMRBC Capital Downgrades Marinus Pharmaceuticals (MRNS)msn.com - April 16 at 9:02 AMMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Neutral" at Robert W. Bairdmarketbeat.com - April 16 at 8:19 AMMaintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Healthmarkets.businessinsider.com - April 15 at 10:35 PMMarinus Pharmaceuticals loses 80% of its market value in one day after setback for new drug candidatebizjournals.com - April 15 at 10:35 PMMarinus Pharmaceuticals (NASDAQ:MRNS) Cut to "Sector Perform" at Royal Bank of Canadamarketbeat.com - April 15 at 1:31 PMBiotech on a Budget: 7 Stocks Under $10 With Huge Potentialinvestorplace.com - April 15 at 12:54 PMMarinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Sessionmarkets.businessinsider.com - April 15 at 12:34 PMWhy Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?msn.com - April 15 at 12:34 PMWhy Are Stocks Up Today?investorplace.com - April 15 at 12:06 PMWhy Is Marinus Pharmaceuticals (MRNS) Stock Down 79% Today?investorplace.com - April 15 at 11:30 AMMarinus Pharmaceuticals' Trial of Therapy For Persistent Seizures Misses Early Stopping Criteriamarketwatch.com - April 15 at 7:34 AMMarinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Resultsbusinesswire.com - April 15 at 7:00 AMmarketbeat.com - April 15 at 6:57 AMMarinus Pharmaceuticals' (MRNS) Overweight Rating Reaffirmed at Cantor Fitzgeraldmarketbeat.com - April 10 at 10:25 AMMarinus Pharmaceuticals Awards Stock Options to New Employees as Inducementmsn.com - April 9 at 1:00 PMMarinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Rating of "Moderate Buy" by Brokeragesmarketbeat.com - April 8 at 2:31 AMMarinus Pharmaceuticals Inc MRNSmorningstar.com - April 5 at 7:50 PMMarinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)businesswire.com - April 5 at 4:00 PMAssenagon Asset Management S.A. Reduces Stock Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)marketbeat.com - April 3 at 4:36 AMMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Reviewfinance.yahoo.com - March 27 at 8:59 AMMarinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus' Post Grant Reviewbusinesswire.com - March 27 at 8:41 AMLeerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:MRNS)marketbeat.com - March 27 at 6:34 AMHC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)marketbeat.com - March 26 at 8:47 AMDo Options Traders Know Something About Marinus (MRNS) Stock We Don't?finance.yahoo.com - March 20 at 1:58 PMMRNS Jul 2024 16.000 callca.finance.yahoo.com - March 15 at 11:44 PMMRNS Mar 2024 7.000 putca.finance.yahoo.com - March 15 at 8:42 AMMarinus Pharmaceuticals (NASDAQ:MRNS) Shares Up 8.5%marketbeat.com - March 12 at 2:34 PMLeerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS)marketbeat.com - March 8 at 7:21 AM Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Gold Set to EXPLODE! (Ad)Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! MRNS Media Mentions By Week MRNS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRNS News Sentiment▼0.180.58▲Average Medical News Sentiment MRNS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRNS Articles This Week▼223▲MRNS Articles Average Week Get Marinus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Aileron Therapeutics News Today Tempest Therapeutics News Today BeyondSpring News Today Connect Biopharma News Today Spero Therapeutics News Today LifeVantage News Today Corvus Pharmaceuticals News Today Vaccitech News Today Leap Therapeutics News Today Barinthus Biotherapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRNS) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & CompanyMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marinus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
